FDA+ roundup: Flurry of guidance documents, updated risk criteria for Covid-19 mAbs, personnel moves and more

The FDA remains without a permanent commissioner but as acting commissioner Janet Woodcock told the Food and Drug Law Institute’s annual conference yesterday, nothing at the agency is slowing down as a result.

With the release of new guidance documents on master protocols and other drug development changes, as well...

Click to view original post